Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027

  • UroGen Pharma (URGN) has surged nearly 180% over the past year and has strong technical momentum.
  • URGN maintains a 100% “Buy” technical opinion from Barchart.
  • The company’s revenue is projected to more than double this year and grow by 56% next year. Earnings are estimated to rise by 75% and 263%, respectively.
  • Despite five years of revenue growth, URGN remains unprofitable, and short interest stands at 12.76% of float with 9.42 days to cover.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.